Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
about
Clinical significance of sIL-2R levels in B-cell lymphomas.A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaPrognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria.Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis.Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma.A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients.Clinical features of de novo CD25(+) diffuse large B-cell lymphoma.Primary CNS lymphoma treated with radiotherapy in Japan: a survey of patients treated in 2005-2009 and a comparison with those treated in 1985-2004.Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients.Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experience.Useful laboratory markers for the diagnosis of bone marrow involvement by malignant lymphoma.Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era.Primary cauda equina lymphoma diagnosed by nerve biopsy: A case report and literature review.Effect of allogeneic blood transfusion on levels of IL-6 and sIL-R2 in peripheral blood of children with acute lymphocytic leukemia.Pre-diagnosis plasma immune markers and risk of non-Hodgkin lymphoma in two prospective cohort studies
P2860
Q35043560-312FADD1-837A-42CA-8CDE-7CDE63A25D2FQ35102683-43843564-8ABF-4D92-A836-B28922EDC181Q36302961-A10DAAEB-D89C-4675-88BC-76977911B129Q36384484-25491DA4-1EA4-4CBC-A26B-EBBC2C423577Q37077176-7DE18993-F1A6-45E5-A388-87BB987D8D37Q37113009-76EB49CF-6EE9-44DC-9E03-A061E671FD99Q39037933-C0072627-4EA5-41A1-992F-79C6F19727E9Q40070997-4825ACEC-35C2-4553-87A4-077BC897C413Q41245405-AA6F2FE7-8BDA-4DF9-A99A-7AFE74409EB3Q43693855-EFBCCFEA-AD8C-43CF-A199-8F5DC32EA02FQ45227780-4BE0A2A9-2C7C-47F1-B389-407775BC92F0Q46459281-A185BD87-4E86-439C-B4F3-FAFA845BBAA1Q46695853-C32E80CA-2A49-4EB8-89DE-87967EE11CF7Q47642100-B65D5D94-7183-44B9-8889-0AAA98FEF5BAQ48028544-CB8ABC7F-DD55-4DDD-8028-3B32ABD8BCF0Q53100526-7F5394BD-621E-4062-BB15-CD8850871215Q55340183-1E8B43C8-CAA8-4054-B0DB-658D54F50404Q55512837-874D6451-7138-4937-B65B-69BA2DDC93A5Q58793783-7C38F1F0-1D8B-4AE5-B5E4-BDB731A23B88
P2860
Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Serum soluble interleukin-2 re ...... treated with R-CHOP regimens.
@en
Serum soluble interleukin-2 receptor
@nl
type
label
Serum soluble interleukin-2 re ...... treated with R-CHOP regimens.
@en
Serum soluble interleukin-2 receptor
@nl
prefLabel
Serum soluble interleukin-2 re ...... treated with R-CHOP regimens.
@en
Serum soluble interleukin-2 receptor
@nl
P2093
P2860
P1433
P1476
Serum soluble interleukin-2 re ...... treated with R-CHOP regimens.
@en
P2093
Hideko Goto
Hisashi Tsurumi
Hisataka Moriwaki
Ichiro Yasuda
Kenji Fukuno
Masahito Shimizu
Nobuo Murakami
Senji Kasahara
Takeshi Hara
P2860
P304
P356
10.1007/S00277-011-1363-4
P577
2011-12-21T00:00:00Z